RESEARCH
Clinical Trials
All studies and references are available upon request.
Full list of Studies for CosaminDS and ingredients.
This List Includes:
Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD.
Glucosamine, Chondroitin and Manganese Ascorbate for Degenerative Joint Disease of the Knee or Low Back: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
Military Medicine, 164(2):85-91, February 1999.
Sixteen-week randomised, double-blind, placebo-controlled crossover study design was implemented. Thirty-four males from the US Navy diving and special warfare community with pain and radiographic cartilage degeneration of the knee or low back were randomised into two groups, intervention (CosaminŽDS) and placebo. A summary score incorporated results of pain and functional questionnaires, physical examination scores and running times. Changes were presented as a percentage of the patient's average score. The authors reported significant improvement among patients in the knee intervention group in comparison the placebo group.
Das AK, Hammad TA.
Efficacy of a Combination of FCHG49™ Glucosamine Hydrochloride, TRH122™ Low Molecular Weight Sodium Chondroitin Sulphate and Manganese Ascorbate in the Management of Knee Osteoarthritis.
Osteoarthritis and Cartilage, 8(5):343-350, 2000.
A double-blind placebo-controlled study recruited 93 patients with cartilage degeneration of the knee for a single centre. Patients were randomised into two groups, intervention (CosaminŽDS) and placebo and were evaluated initially and then every two months for six months. The authors reported that patients with mild or moderate radiographic changes showed significant improvement at four and six months in comparison to the placebo group.
Schenck RC, Clare DJ, Gilley JS et al.
Role of Glucosamine/Chondroitin Sulphate Formula in Treatment of an Osteochondral Impaction Injury in a Collegiate Basketball Player.
Orthopaedic Technology Review, 2(7):12-15, July/August, 2000.
Case history with repeat MRI and CT bone scans support that patients sustaining osteochondral impaction injury could benefit from CosaminŽDS administration.
